Scholarlink

<p>Hepatocellular carcinoma (HCC), the most common form of primary liver cancer, is frequently diagnosed at advanced stages, limiting curative options. Multi-kinase inhibitors (MKIs), such as sorafenib and lenvatinib, serve as first-line therapies for unresectable HCC. However, the widespread development of drug resistance significantly diminishes the clinical efficacy of MKIs, and current treatments lack effective strategies to enhance MKI sensitivity. Metabolic reprogramming, a hallmark of cancer cells that facilitates unchecked growth and metastasis, has emerged as a critical mechanism driving MKI resistance in HCC. This review comprehensively examines the roles of glycolysis, lipid metabolism, and amino acid metabolism in promoting MKI resistance, with a focus on key molecular regulators that could serve as potential targets to reverse resistance. Additionally, this review synthesizes preclinical and clinical evidence of therapeutic agents that synergize with MKIs by modulating metabolic pathways, and discusses the regulatory role of metabolic reprogramming in the tumor immune microenvironment (TIME) of HCC, offering innovative strategies to improve treatment outcomes for patients with HCC. These findings highlight metabolic reprogramming as a crucial target for developing novel interventions aimed at overcoming MKI resistance in clinical practice.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Metabolic reprogramming-driven resistance to multi-kinase inhibitors in hepatocellular carcinoma: molecular mechanisms and therapeutic opportunities

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年1月27日

查看全文
  • Junxin Li,
  • Yu Huang,
  • Jiawei Li,
  • Min Shi,
  • Yi Xiao,
  • Fei Du,
  • Gongli Hu

摘要

Hepatocellular carcinoma (HCC), the most common form of primary liver cancer, is frequently diagnosed at advanced stages, limiting curative options. Multi-kinase inhibitors (MKIs), such as sorafenib and lenvatinib, serve as first-line therapies for unresectable HCC. However, the widespread development of drug resistance significantly diminishes the clinical efficacy of MKIs, and current treatments lack effective strategies to enhance MKI sensitivity. Metabolic reprogramming, a hallmark of cancer cells that facilitates unchecked growth and metastasis, has emerged as a critical mechanism driving MKI resistance in HCC. This review comprehensively examines the roles of glycolysis, lipid metabolism, and amino acid metabolism in promoting MKI resistance, with a focus on key molecular regulators that could serve as potential targets to reverse resistance. Additionally, this review synthesizes preclinical and clinical evidence of therapeutic agents that synergize with MKIs by modulating metabolic pathways, and discusses the regulatory role of metabolic reprogramming in the tumor immune microenvironment (TIME) of HCC, offering innovative strategies to improve treatment outcomes for patients with HCC. These findings highlight metabolic reprogramming as a crucial target for developing novel interventions aimed at overcoming MKI resistance in clinical practice.